中重度斑块型银屑病患者血清白介素-17、抗菌肽LL-37水平与颈动脉粥样硬化的关系

doi:10.3870/j.issn.1672-8009.2026.05.009

医学分子生物学杂志 ›› 2026, Vol. 23 ›› Issue (5): 549-555.doi: 10.3870/j.issn.1672-8009.2026.05.009

中重度斑块型银屑病患者血清白介素-17、抗菌肽LL-37水平与颈动脉粥样硬化的关系

赵旭明¹, 柴琴琴², 李亚维¹, 景晓蕾¹, 刘晓静¹, 杨晓静¹, 孟昭影¹

河北北方学院附属第一医院 ¹皮肤科, ²神经内科河北省张家口, 075000

收稿日期:2025-12-14 出版日期:2026-09-30 发布日期:2026-09-30
通讯作者: 孟昭影（E-mail：1076502992@qq.com）
基金资助:
河北省卫生健康委员会医学科学研究课题计划（No.20260800）

Relationship Between Serum Interleukin-17, Cathelicidin Antimicrobial Peptide 37 Levels and Carotid Atherosclerosis in Patients with Moderate-to-Severe Plaque Psoriasis

ZHAO Xuming¹, CHAI Qinqin², LI Yawei¹, JING Xiaolei¹, LIU Xiaojing¹, YANG Xiaojing¹, MENG Zhaoying¹

¹Departement of Dermatology, ²Departement of Neurology, the First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, China

Received:2025-12-14 Online:2026-09-30 Published:2026-09-30
Contact: MENG Zhaoying（E-mail：1076502992@qq.com）
Supported by:
Medical Research Program of the Hebei Provincial Health Commission（No.20260800）

摘要/Abstract

摘要： 目的研究中重度斑块型银屑病患者血清白介素-17（interleukin-17,IL-17）、抗菌肽LL-37 水平与颈动脉粥样硬化的关系。方法选择2023年6月~2024年12月收治的168例中重度斑块型银屑病患者,检测血清IL-17和LL-37水平。根据颈动脉内膜中层厚度（intima-media thickness,IMT）将患者分为粥样硬化组（IMT≥1.5 mm,n=56）和非粥样硬化组（IMT<1.5 mm,n=112）,比较两组患者临床资料及血清IL-17、LL-37的差异,采用Pearson检验分析血清IL-17、LL-37与IMT的相关性,采用logistic回归分析颈动脉粥样硬化的影响因素,采用ROC曲线分析血清指标对颈动脉粥样硬化的诊断价值。结果粥样硬化组的银屑病皮损面积和严重程度指数及血清低密度脂蛋白胆固醇（low-density lipoprotein cholesterol,LDLC）、C反应蛋白、尿酸、IL-17、LL-37水平高于非粥样硬化组（P<0.05）;血清IL-17、LL-37与颈动脉IMT呈显著正相关关系（P<0.05）;IL-17升高（OR=1.255）、LL-37升高（OR=1.014）、LDLC升高（OR=13.278）是颈动脉粥样硬化的危险因素（P<0.05）;IL-17、LL-37、LDLC诊断颈动脉粥样硬化的曲线下面积分别为0.861、0.848、0.702;IL-17、LL-37诊断颈动脉粥样硬化的曲线下面积高于LDLC（P<0.05）,IL-17与LL-37曲线下面积比较的差异无统计学意义（P>0.05）。结论中重度斑块型银屑病患者血清IL-17、LL-37升高与颈动脉粥样硬化相关,IL-17、LL-37作为颈动脉粥样硬化诊断标志物的诊断效能优于LDLC。

关键词: 中重度斑块型银屑病, 颈动脉粥样硬化, 血清白介素-17, 抗菌肽LL-37, 危险因素

Abstract: Objective To investigate the relationship between serum interleukin-17 （IL-17）, cathelicidin antimicrobial peptide LL-37 levels and carotid atherosclerosis in patients with moderate-to-severe plaque psoriasis. Methods A total of 168 patients with moderate-to-severe plaque psoriasis admitted between June 2023 and December 2024 were selected and serum IL-17 and LL-37 levels were measured.According to cartid intima-media thickness（IMT）, patients were divided into atherosclerosis group （IMT ≥1.5 mm, n=56） and non-atherosclerosis group （IMT <1.5 mm, n=112）. Clinical data and serum IL-17 and LL-37 levels were compared between the two groups. We used Pearson correlation analysis to evaluate the association between serum IL-17, LL-37 levels and IMT. Additionally, logistic regression analysis was applied to determine the factors affecting carotid atherosclerosis. Additionally, receiver operating characteristic （ROC） curve analysis was conducted to evaluate the diagnostic efficacy of serum biomarkers for carotid atherosclerosis. Results The Psoriasis Area and Severity Index score and levels of low-density lipoprotein cholesterol （LDLC）, C-reactive protein, uric acid, IL-17 and LL-37 in serum of the atherosclerosis group were higher than those of the non-atherosclerosis group （P<0.05）. Serum IL-17 and LL-37 showed significant positive correlations with carotid IMT （P<0.05）. Elevated IL-17 （OR=1.255）, elevated LL-37 （OR=1.014）, and elevated LDLC （OR=13.278） were risk factors for carotid atherosclerosis （P<0.05）. The areas under the curve （AUC） of IL-17, LL-37, LDLC for diagnosing carotid atherosclerosis were 0.861, 0.848, 0.702, respectively. The AUCs for IL-17 and LL-37 in diagnosing carotid atherosclerosis were higher than those for LDLC （P<0.05）, and there was no statistically significant difference in the AUCs between IL-17 and LL-37 （P>0.05）. Conclusion Elevated serum IL-17 and LL-37 levels are associated with carotid atherosclerosis in patients with moderate-to-severe plaque psoriasis. The diagnostic efficacy of IL-17 and LL-37 as diagnostic markers for carotid atherosclerosis is superior to that of LDLC.

Key words: moderate-to-severe plaque psoriasis, carotid atherosclerosis, serum interleukin-17, LL-37, risk factors

中图分类号:

R758.63

赵旭明, 柴琴琴, 李亚维, 景晓蕾, 刘晓静, 杨晓静, 孟昭影. 中重度斑块型银屑病患者血清白介素-17、抗菌肽LL-37水平与颈动脉粥样硬化的关系[J]. 医学分子生物学杂志, 2026, 23(5): 549-555.

ZHAO Xuming, CHAI Qinqin, LI Yawei, JING Xiaolei, LIU Xiaojing, YANG Xiaojing, MENG Zhaoying. Relationship Between Serum Interleukin-17, Cathelicidin Antimicrobial Peptide 37 Levels and Carotid Atherosclerosis in Patients with Moderate-to-Severe Plaque Psoriasis[J]. Journal of Medical Molecular Biology, 2026, 23(5): 549-555.

参考文献

[1] BULSEI J,FONTAS E,HUBICHE T,et al.Ischemic cerebral stroke risk under psoriasis and psoriatic arthritis treatment: A real-world observational study from the French national healthcare system database[J]. J Eur Acad Dermatol Venereol,2023,37(12):e1447-e1448.
[2] OSIGWE P C,AGOMOH C E,OSIGWE I S,et al.The association between psoriasis and atherosclerotic cardiovascular disease: A systematic review and meta-analysis of observational studies[J]. Cureus,2024,16(6):e63379.
[3] MEDAMANA J L,GELFAND J M,WEBER B N,et al.Cardiovascular disease risk in psoriatic disease: Mechanisms and implications for clinical practice[J]. Curr Opin Rheumatol,2025,37(4):261-268.
[4] SVEDBOM A,MALLBRIS L,GONZÁLEZ-CANTERO Á,et al. Skin inflammation,systemic inflammation,and cardiovascular disease in psoriasis[J]. JAMA Dermatol,2025,161(1):81-86.
[5] 胡华,付丹丹,李佳林,等. 中重度斑块型银屑病患者血清IL-33表达水平及其与颈动脉粥样硬化的相关性分析[J]. 中国皮肤性病学杂志,2025,39(3):273-279.
HU H,FU D D,LI J L,et al.Analysis of serum IL-33 expression level and its correlation with carotid atherosclerosis in patients with moderate to severe plaque psoriasis[J]. Chin J Dermatovenereology,2025,39(3):273-279.
[6] 卢晓燕,甘泉,甘才斌. 中-重度斑块型银屑病患者颈动脉粥样硬化的危险因素分析[J]. 中国中西医结合皮肤性病学杂志,2021,20(5):466-470.
LU X Y,GAN Q,GAN C B.Risk factors of carotid atheroscleosis in patients with moderate to severe plaque psoriasis[J]. Chin J Dermatovenerol Integr Tradit West Med,2021,20(5):466-470.
[7] YAO Y,CHEN L Q,LV Y B,et al.Skin immune microenvironment in psoriasis: From bench to bedside[J]. Front Immunol,2025,16:1643418.
[8] PALAZZO E,LOTTI R,QUADRI M,et al.IL-17 ligand and receptor family members are differentially expressed by keratinocyte subpopulations and modulate their differentiation and inflammatory phenotype[J]. Int J Mol Sci,2025,26(7):2989.
[9] NAKAMURA Y,KULKARNI N N,TAKAHASHI T,et al.Increased LL37 in psoriasis and other inflammatory disorders promotes LDL uptake and atherosclerosis[J]. J Clin Invest,2024,134(5):e172578.
[10] 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2023版)[J]. 中华皮肤科杂志, 2023, 56(7): 573-625.
Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition)[J]. Chin J Dermatol, 2023, 56(7): 573-625.
[11] 上海市超声质量控制中心. 颈动脉粥样硬化斑块超声规范化操作及报告专家共识(2025,上海)[J/OL]. 中华医学超声杂志(电子版),2025,22(6):504-515.
Shanghai Ultrasound Quality Control Center.Expert consensus on standardized operation and reporting of carotid ultrasound (2025,Shanghai)[J/OL]. Chin J Med Ultrasound Electron Ed,2025,22(6):504-515.
[12] MATWIEJUK M,MYŚLIWIEC H,MIKŁOSZ A,et al. The association between psoriasis and metabolic syndrome in children: A narrative review[J]. Metabolites,2025,15(6):377.
[13] RUAN Z,LU T,CHEN Y,et al.Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults[J]. JAMA Dermatol,2022,158(7):745-753.
[14] FANG N,JIANG M,FAN Y.Association between psoriasis and subclinical atherosclerosis: A meta-analysis[J]. Medicine,2016,95(20):e3576.
[15] ALIMUJIANG A,KANG Y,WEI W,et al.Apigenin suppresses keratinocyte hyperproliferation and inflammation in psoriasis by inhibiting CDK2/E2F2 pathway[J]. Phytomedicine,2025,144:156486.
[16] JOO K,KARSULOVIC C,SORE M,et al.Pivotal role of mTOR in non-skin manifestations of psoriasis[J]. Int J Mol Sci,2024,25(12):6778.
[17] 李鹏,张洁,吕忠英. 白细胞介素17与2型糖尿病患者冠状动脉非钙化斑块负荷的相关性及其对不良心血管事件的预测价值[J]. 中国医师进修杂志,2024,47(12):1057-1060.
LI P,ZHANG J,LYU Z Y.Correlation between interleukin-17 and coronary atherosclerotic plaque load in type 2 diabetes mellitus patients and its predictive value for adverse cardiovascular events[J]. Chin J Postgrad Med,2024,47(12):1057-1060.
[18] GUO J,HU Z,REN L,et al.Circulating tumor necrosis factor-α,interleukin-1β,and interleukin-17A estimates increased major adverse cardiac event risk in acute myocardial infarction patients[J]. J Clin Lab Anal,2023,37(5):e24853.
[19] ISLAM R K,MALTESE A,ISLAM K N,et al.Reduced major adverse cardiovascular events with interleukin-17 inhibitors compared to methotrexate in psoriasis patients: A multicenter retrospective cohort analysis[J]. J Am Acad Dermatol,2025,93(1):268-270.
[20] NAKANISHI T,IIDA S,ICHISHI M,et al.Amelioration of systemic amyloidosis by blocking IL-17A and not by IL-17F,and arteriosclerosis by blocking both IL-17A and IL-17F in an inflammatory skin mouse model[J]. Int J Mol Sci,2024,25(21):11617.
[21] FENG C,ZHANG H,WANG P,et al.Oroxylin A suppress LL-37 generated rosacea-like skin inflammation through the modulation of SIRT3-SOD2-NF-κB signaling pathway[J]. Int Immunopharmacol,2024,129:111636.
[22] MECA A D,ȘTEFĂNESCU S,BOGDAN M,et al. Crosstalk between vitamin D axis,inflammation and host immunity mechanisms: A prospective study[J]. Exp Ther Med,2021,21(6):608.
[23] MIAO S,LIU H,YANG Q,et al.Cathelicidin peptide LL-37: A multifunctional peptide involved in heart disease[J]. Pharmacol Res,2024,210:107529.
[24] SI F,LU Y,WEN Y,et al.Cathelicidin (LL-37) causes expression of inflammatory factors in coronary artery endothelial cells of Kawasaki disease by activating TLR4-NF-κB-NLRP3 signaling[J]. Immun Inflamm Dis,2023,11(9):e1032.
[25] DAHL S,CERPS S,RIPPE C,et al.Human host defense peptide LL-37 facilitates double-stranded RNA pro-inflammatory signaling through up-regulation of TLR3 expression in vascular smooth muscle cells[J]. Inflamm Res,2020,69(6):579-588.

中重度斑块型银屑病患者血清白介素-17、抗菌肽LL-37水平与颈动脉粥样硬化的关系

Relationship Between Serum Interleukin-17, Cathelicidin Antimicrobial Peptide 37 Levels and Carotid Atherosclerosis in Patients with Moderate-to-Severe Plaque Psoriasis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价